Evidence map›Paper›PMID 42057203›Full record

ArticleBMC chemistry2026

Development of a novel LC-MS/MS method for concurrent determination of imipenem, relebactam, and cilastatin in human serum, urine and peritoneal drainage fluid.

Xiaoyu Yang, Chaoyue Zhao, Yiwen Ding, Yining Li, Yushang Zhao, Wanling Lin, Jing Li, Dong Wang, Zhihong Yue, Lin Pei and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiaoyu Yang *Department of Clinical Laboratory, Peking University People's Hospital, Xizhimen South Street No. 11, Beijing, 100044, China.
Chaoyue Zhao *Department of Clinical Laboratory, Peking University People's Hospital, Xizhimen South Street No. 11, Beijing, 100044, China.
Yiwen Ding *Department of Clinical Laboratory, Sixth Affiliated Hospital of Kunming Medical University, Yuxi, 653100, China.
Yining LiDepartment of Clinical Laboratory, Peking University People's Hospital, Xizhimen South Street No. 11, Beijing, 100044, China.
Yushang ZhaoDepartment of Clinical Laboratory, Peking University People's Hospital, Xizhimen South Street No. 11, Beijing, 100044, China.
Wanling LinDepartment of Clinical Laboratory, Peking University People's Hospital, Xizhimen South Street No. 11, Beijing, 100044, China.
Jing LiDepartment of Laboratory Medicine, Inner Mongolia Medical College Hospital, Hohhot, 010010, China.
Dong WangShanghai AB Sciex Analytical Instrument Trading Co., Ltd, Shanghai, 201100, China.
Zhihong YueDepartment of Clinical Laboratory, Peking University People's Hospital, Xizhimen South Street No. 11, Beijing, 100044, China.
Lin PeiDepartment of Clinical Laboratory, Peking University People's Hospital, Xizhimen South Street No. 11, Beijing, 100044, China.
Mei JiaDepartment of Clinical Laboratory, Peking University People's Hospital, Xizhimen South Street No. 11, Beijing, 100044, China.
Lin-Lin CaoDepartment of Clinical Laboratory, Peking University People's Hospital, Xizhimen South Street No. 11, Beijing, 100044, China. caoll@bjmu.edu.cn.
Hui WangDepartment of Clinical Laboratory, Peking University People's Hospital, Xizhimen South Street No. 11, Beijing, 100044, China. whuibj@163.com.

Funding

Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation BMU2024YFJHPY023Peking University People's Hospital Scientific Research Development Funds RDJP2022-57, RDX2023-13
6 · The paper itself

Abstract

With the global spread of antimicrobial resistance (AMR), infections caused by multidrug-resistant bacteria have become a major challenge in clinical treatment. 'Imipenem, Cilastatin Sodium and Relebactam for Injection' is a critical therapeutic agent for treating infections caused by multidrug-resistant Gram-negative bacteria. However, it is associated with gastrointestinal adverse reactions, necessitating therapeutic drug monitoring (TDM) for precise dosing. Currently, there is no method for simultaneously detecting the concentrations of all three components in 'Imipenem, Cilastatin Sodium and Relebactam for Injection'. Therefore, this study established an analytical method based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the simultaneous quantification of imipenem, relebactam, and cilastatin in serum, urine, and peritoneal drainage fluid (PD). After protein precipitation, samples were separated using a CORTECS

Indexed as

CilastatinImipenemLiquid chromatography-tandem mass spectrometry (LC-MS/MS)RelebactamTherapeutic drug monitoring (TDM)

Identifiers

PMID42057203
PMCPMC13273956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.